Intermittent administered erlotinib plus carboplatin, paclitaxel, bebacizumab in patients with advanced lung cancer.

Phase II, multicenter, open study , first line treatment of intermittenty administered Erlotinib plus Carboplatin, paclitaxel and bebacizumab in patients with advanced none small and none squamous lung cancer. - avaFAST

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-006313-33-ES

Enrollment

Unknown

Registered

2012-01-27

Start date

2012-03-21

Completion date

Unknown

Last updated

2016-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: TARCEVA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ERLOTINIB CAS Number: 183321-74-6 Concentration unit: mg milligram(s) Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 64 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 64

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Spain

Contacts

Public ContactPIVOTAL (Maria Moreno)

PIVOTAL

maria.moreno@pivotal.es34917081250

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026